News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cambria Biosciences Receives $5.0 Million in Grants and Awards for Neurodegenerative Disease Drug Discovery and Preclinical Development Programs


11/12/2007 11:38:18 AM

WOBURN, Mass.--(BUSINESS WIRE)--Cambria Biosciences, a privately held biopharmaceutical company focused on the discovery and development of innovative proprietary small molecule drugs for neurological conditions, today announced that it has been awarded five grants from multiple organizations totaling $5.0 million. The grant funding will support the company’s drug discovery programs for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), muscular dystrophy and Parkinson’s disease.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES